Events

20 – 23 May: Euro PCR

March 11, 2025

Date

20 – 23 May

Location

Paris

Recor Symposium

Tuesday May 20th, 4.30 – 5.30 pm
Room 243

Ultrasound Renal Denervation is now guideline-recommended: how do I get started?

Anchorperson

Prof. Andrew Sharp

Spokesperson

Prof. Flavio Ribichini

Discussants / speakers

Prof. Sofie Brouwers
Dr. Joost Daemen
Prof. Stefan Toggweiler

Topics

RDN Works! The Sham controlled trial data that prove it (Dr. Joost Daemen)
Applying the new European Guidelines to the patient (Prof. Sofie Brouwers)
How to set up a uRDN Programme (Prof. Stefan Toggweiler)
Podium Discussion: The next steps for uRDN

Back to Overview

23 – 26 May: European Meeting on Hypertension and Cardiovascular Protection (ESH)
March 11, 2025
Advancing Hypertension Management: Renal Denervation in clinical practice

Privacy Statement | Terms & Conditions | Corporate Governance | Patents | Connect

The PARADISE™ system is FDA approved for sale in the United States and is CE marked and approved for sale in markets where the CE mark is accepted.

© 2025 Recor Medical, Inc. All rights reserved. The PARADISE™ system is FDA approved for sale in the United States and is CE marked and approved for sale in markets where the CE mark is accepted, per approved indications for use. For investigational use only in Japan. RECOR MEDICAL, PARADISE, HYDROCOOLING, SONOWAVE 360, RADIANCE, the GPS logo, and the Swirl logo are registered trademarks in the EU and the other countries, RECOR and the RADIANCE logo are also trademarks of Recor Medical, Inc. EMEA 03/2025

Important Safety Information
Prescription Only. Brief Summary – Prior to use, please reference the Instructions for Use

Indications for Use
The Paradise™ Ultrasound Renal Denervation System (Paradise™ System) is indicated to reduce blood pressure as an adjunctive treatment in hypertension patients in whom lifestyle modifications and antihypertensive medications do not adequately control blood pressure.

Results may vary. The most common risks include pain, vascular site injury and vasospasm. See full important safety information: https://www.recormedical.eu/paradise-ultrasound-rdn-system/#safety

Recor Medical, headquartered in Palo Alto, California, USA, a wholly owned subsidiary of Otsuka Medical Devices Co., Ltd. recormedical.eu is Recor Medical, Otsuka Medical Devices Europe GmbH website (the Site). We control and operate this Site from Europe. This Site is intended for use by European residents only and contains information regarding the Paradise™ System, which is approved for sale in the EU and bears a CE mark.

Recor Medical Europe GmbH
Europa-Allee 52 · 60327 Frankfurt · Germany
Amtsgericht Frankfurt am Main: HRB 123214
Chief Executive Officers: Lara Barghout, Michael Jones, Ronan O`Connor

20 – 23 May: Euro PCR

Topics

23 – 26 May: European Meeting on Hypertension and Cardiovascular Protection (ESH)